Trial reportInternational journal of colorectal disease2013
Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double-blind placebo-controlled study of 24-month duration.
Trial report in International journal of colorectal disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 7 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- German guideline diverticular disease/diverticulitis: Part II: Conservative, interventional and surgical management.United European gastroenterology journal · 2022Guideline
- Recurrence of Uncomplicated Diverticulitis: A Meta-Analysis.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials.Canadian journal of gastroenterology & hepatology · 2018Pooled it
- Mesalamine (5-ASA) for the prevention of recurrent diverticulitis.The Cochrane database of systematic reviews · 2017Pooled it
- Risk factors for recurrence after acute colonic diverticulitis: a systematic review.International journal of colorectal disease · 2017Pooled it
- Mesalamine Does Not Help Prevent Recurrent Acute Colonic Diverticulitis: Meta-Analysis of Randomized, Placebo-Controlled Trials.The American journal of gastroenterology · 2016Pooled it
- Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines.Techniques in coloproctology · 2015Guideline
- Effects of Burdock tea on recurrence of colonic diverticulitis and diverticular bleeding: An open-labelled randomized clinical trial.Scientific reports · 2019Trial
- Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence.Alimentary pharmacology & therapeutics · 2017Trial
- Risk-stratified pharmacologic strategies for secondary prevention after acute diverticulitis: an exploratory narrative review and research framework.Frontiers in surgery · 2026Review
- Unmet needs in treatment of symptomatic uncomplicated diverticular disease and prevention of recurrent acute diverticulitis: a scoping review.Therapeutic advances in gastroenterology · 2024Article
- The Association of Coloproctology of Great Britain and Ireland consensus guidelines in emergency colorectal surgery.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2021Article
- Development and validation of a diverticular clinical score for symptomatic uncomplicated diverticular disease after acute diverticulitis in a prospective patient cohort.Therapeutic advances in gastroenterology · 2020Article
- Epidemiology, Pathophysiology, and Treatment of Diverticulitis.Gastroenterology · 2019Review
- Inflammation management in acute diverticulitis: current perspectives.Journal of inflammation research · 2018Review
- Progress and challenges in the management of diverticular disease: which treatment?Therapeutic advances in gastroenterology · 2018Review
- Conservative Treatment of Acute Colonic Diverticulitis.Current infectious disease reports · 2017Review
- [Diverticulitis : Domain of conservative or drug therapy?]Der Internist · 2017Review
- Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study.United European gastroenterology journal · 2016Article
- Recent Advances in Diverticular Disease.Current gastroenterology reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimRecurrence of diverticulitis is frequent within 5 years from the uncomplicated first attack, and its prophylaxis is still unclear. We have undertaken a multicentre, randomised, double-blind, placebo-controlled pilot study in order to evaluate the role of mesalazine in preventing diverticulitis recurrence as well as its effects on symptoms associated to diverticular disease.
methodsNinety-six patients with the recent first episode of uncomplicated diverticulitis were randomised to receive mesalazine 800 mg twice daily for 10 days every month or placebo for 24 months. The primary efficacy end point was the diverticulitis recurrence at intention to treat analysis. Clinical evaluations were performed using the Therapy Impact Questionnaire (TIQ) for physical condition and quality of life at admission and at 3-month intervals. Treatment tolerability and routine biochemistry parameters as well as the use of additional drugs were also evaluated.
resultsNinety-two patients (mean age, 61.5) completed the study, 45 of whom received mesalazine, and 47, placebo. Diverticulitis relapse incidence in mesalazine-treated group was 5/45 (11%) at the 12th month and 6/45 (13%) at the 24th month; in the placebo-treated group, the correspondent rates were 13% (6/47) and 28% (13/47), respectively. Mean values of TIQ at 24 months were significantly better in mesalazine-treated group than in placebo-treated group (p = 0.02); in addition, average additional drug consumption was significantly lower (-20.4%, p < 0.03) in mesalazine than in placebo.
conclusionsDiverticulitis recurrence occurred in as many as 28% of patients under placebo within 24 months from the initial episode. Intermittent prophylaxis with mesalazine did not significantly reduce the risk of relapse but induced a significant improvement of patients' physical conditions and significantly lowered the additional consumption of other gastrointestinal drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.